Skip to main content

Advertisement

SpringerLink
Log in

Immunobiology and immunotherapy of head and neck cancer

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

The development of head and neck cancer (HNC) is strongly influenced by the host immune system. Immunoselection of tumors resistant to immune attack and the ability of established tumors to disarm or eliminate immune cells favor tumor progression. Recent evidence for local as well as systemic apoptosis of T lymphocytes, the paucity of dendritic cells (DC) at the tumor site, or the presence of signaling defects in T lymphocytes of patients with HNC emphasizes the fact that their antitumor responses are compromised. The clinical and biologic importance of these immune biomarkers is revealed by the finding that they appear to independently predict 5-year survival in patients with oral carcinoma. Whereas the mechanisms responsible for immune dysfunction in HNC are being investigated, new immunotherapeutic strategies, including antitumor vaccines and DC-based interventions, aim at the restoration of tumor-targeted immune responses. These novel biologic therapies, alone or in combination with conventional therapies, might be expected to protect immune cells from dysfunction or death and to enhance their antitumor activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Califano J, van der Reit P, Westra W, et al.: A genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996, 56:2488–2492.

    PubMed  CAS  Google Scholar 

  2. Nawroz H, van der Reit P, Hruban RH, et al.: Allelotype of head and neck squamous cell carcinoma. Cancer Res 1994, 54:1152–1155.

    PubMed  CAS  Google Scholar 

  3. Wiedenfeld EA, Fernandez-Vina M, Berzofsky JA, Carbone DP:Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA-A0201 peptide consensus motif. Cancer Res 1994, 54:1175–1177.

    PubMed  CAS  Google Scholar 

  4. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000, 74:181–273.

    Article  PubMed  CAS  Google Scholar 

  5. Atarashi Y, Stanson J, Rabinowich H, et al.: Resistance of tumor cells to Fas-mediated apoptosis in head and neck cancer [abstract]. AACR Proc 2000, 41:557.

    Google Scholar 

  6. Young MRI, Schmidt-Pak A, Wright MA, et al.: Mechanisms of immune suppression in patients with head and neck cancer: presence of immune suppressive CD34+ cells in cancers that secrete granulocyte-macrophage colony stimulating factor. Clin Cancer Res 1995, 1:95–103.

    PubMed  Google Scholar 

  7. Saito T, Kuss I, Dworacki G, et al.: Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 1999, 5:1263–1273. Provides evidence that, among circulating T cells in patients with HNC, many are predestined to undergo apoptosis. The subgroup of patients with a high percentage of spontaneously apoptotic cells in the circulation was not clinically different from that with a low percentage of apoptotic T cells in PBMC, except that the latter patients tended to have well-differentiated tumors. The data suggest that an increased rate of turnover of lymphocytes is associated with HNC.

    PubMed  CAS  Google Scholar 

  8. Whiteside TL: Tumor-infiltrating Lymphocytes in Human Malignancies. Austin, TX: RG Landes; 1993.

    Google Scholar 

  9. Goldman SA, Baker E, Weyant RJ, et al.: Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 1998, 124:641–646.

    PubMed  CAS  Google Scholar 

  10. Whiteside TL: Tumor-infiltrating lymphocytes in head and neck cancer. In Immunotherapy of Cancer with Sensitized T Lymphocytes. Edited by Chang AE, Shu S. Austin, TX: RG Landes; 1994:133–154.

    Google Scholar 

  11. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL: Human immune cells in the tumor microenvironment: mechanisms responsible for signaling and functional defects. J Immunother 1998, 21:295–306.

    Article  PubMed  CAS  Google Scholar 

  12. Reichert TE, Day R, Wagner EM, Whiteside TL: Absent or low expression of the ξ chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998, 58:5344–5347. The authors studied expression of the TcR-associated ξ chain by immunocytochemistry in T cells infiltrating oral carcinomas (n=132). Patients with stage III and IV disease and with tumors infiltrated by T cells expressing absent or low ξ expression were found to have significantly shorter 5-year survival than patients with T cells expressing normal ξ expression in situ. Thus, ξ expression was found to be a significant prognostic factor in oral carcinoma, independent of such established prognostic markers as stage or nodal involvement.

    PubMed  CAS  Google Scholar 

  13. Young MRI, Wright MA, Lozano Y, et al.: Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 1996, 67:333–338.

    Article  PubMed  CAS  Google Scholar 

  14. Dworacki G, Meidenbauer N, Sato T, et al.: Spontaneous ex vivo apoptosis of peripheral blood CD8+ T cells may contribute to systemic immuno-suppression in patients with head and neck cancer (HNC) [abstract]. International Conference on Head and Neck Cancer 2000: PA349.

  15. Reichert TE, Scheuer C, Day R, et al.: Clinical and prognostic significance of p55+ and S-100+ human dendritic cells in the microenvironment of oral carcinoma [abstract]. International Conference on Head and Neck Cancer 2000:PA316.

  16. Kuss I, Saito T, Johnson JT, Whiteside TL: Clinical significance of decreased ξ chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 1999, 5:329–334. Expression of the ξ chain in circulating T and NK cells of patients with HNC was evaluated by flow cytometry and compared with that in lymphocytes of age-matched normal donors. Low ξ expression was observed in lymphocytes of patients with HNC but no evident disease at the time of this study. The lowest levels of ξ expression were found in patients who had been treated by surgery only for recurrent tumors in the last 2 years.

    PubMed  CAS  Google Scholar 

  17. Saito T, Dworacki G, Gooding W, et al.: Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res 2000, 6:1351–1364. Spontaneous apoptosis of circulating T cells occurs not only in patients with HNC but also in those with advanced melanoma. Importantly, patients previously treated with biotherapies had significantly fewer apoptotic T cells than those not so treated.

    PubMed  CAS  Google Scholar 

  18. Whiteside TL, Rabinowich H: The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 1998, 46:175–184. This review of factors and mechanisms that might be responsible for immunosuppression in patients with cancer is recommended for the reader interested in this topic.

    Article  PubMed  CAS  Google Scholar 

  19. Gastman BR, Atarashi Y, Reichert TE, et al.: Fas ligand is expressed on human squamous cell carcinomas of the head and neck and it promotes apoptosis of T lymphocytes. Cancer Res 1999, 59:5356–5364. The involvement of the Fas/FasL pathway in apoptosis of T cells in patients with HNC is described at the functional and molecular levels. Expression of FasL on HNC cells is documented by immunotherapy, Western blots, and RT-PCR. Its ability to cause T-cell apoptosis is confirmed by antibody blocking, use of Jurkat cells resistant to apoptosis, and pre-incubation of T cells with caspase inhibitors.

    PubMed  CAS  Google Scholar 

  20. Sato T, Irie S, Kitada S, Reed JC: FAP-1: A protein tyrosine phosphatase that associates with Fas. Science 1995, 268:411–415.

    Article  PubMed  CAS  Google Scholar 

  21. Lee PP, Yee C, Savage PA, et al.: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999, 5:677–685. Evidence is provided, using tetrameter staining, that circulating T cells specific for melanoma peptides are selectively eliminated in patients with melanoma. In contrast, T-cell precursors specific for EBV antigens are not eliminated.

    Article  PubMed  CAS  Google Scholar 

  22. Yee C, Savage PA, Lee PP, et al.: Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999, 162:2227–2234.

    PubMed  CAS  Google Scholar 

  23. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics. CA Cancer J Clin 1996, 46:5–27.

    PubMed  CAS  Google Scholar 

  24. Medina JE: The controversial role of BCG in treatment of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1993, 109:543.

    Google Scholar 

  25. Whiteside TL, Letessier E, Hirabayashi H, et al.: Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res 1993, 53:5654–5662.

    PubMed  CAS  Google Scholar 

  26. Richtsmeyer WJ, Koch WM, McGuire WP, et al.: Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant interferon gamma. Arch Otolaryngol Head Neck Surg 1990, 116:1271–1277.

    Google Scholar 

  27. Vlock DR, Johnson J, Myers E, et al.: Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck. Head Neck 1991, 13:15–21.

    Article  PubMed  CAS  Google Scholar 

  28. Shu S, Chou T, Sakai K: Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol 1989, 143:740–748.

    PubMed  CAS  Google Scholar 

  29. Whiteside TL: Cellular adoptive immunotherapy: expectations and reality. In The Biotherapy of Cancers: From Immunotherapy to Gene Therapy. Edited by Chouaib S. Paris: Les Editions INSERM; 1998:239–262.

    Google Scholar 

  30. To WC, Wood BG, Krauss JC, et al.: Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head neck: a phase I study. Arch Otolaryngol Head Neck Surg 2000, 126:1225–1231.

    PubMed  CAS  Google Scholar 

  31. Chikamatsu K, Nakano K, Storkus WJ, et al.: Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 1999, 5:1281–1288.

    PubMed  CAS  Google Scholar 

  32. Shichijo S, Nakao M, Imai Y, et al.: A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998, 187:277–288.

    Article  PubMed  CAS  Google Scholar 

  33. Mandruzzato S, Brasseur F, Andry G, et al.: A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997, 186:785–793.

    Article  PubMed  CAS  Google Scholar 

  34. Lotze MT, Shurin M, Davis I, et al.: Dendritic cell based therapy of cancer. In Dendritic Cells in Fundamental Clinical Immunology. Edited by Ricciardi-Castagnoli P. New York: Plenum; 1997:551–569.

    Google Scholar 

  35. Chikamatsu K, Reichert TE, Kashii et al.: Immunotherapy with effector cells and IL-2 of lymph node metastases of human squamous cell carcinoma of the head and neck established in nude mice. Int J Cancer 1999, 82:532–537.

    Article  PubMed  CAS  Google Scholar 

  36. Hoffmann TKH, Meidenbauer N, Dworacki G, et al.:Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000, 60:3542–3549. Apoptotic HNC cells can be taken up, processed, and presented to tumor-specific T cells by dendritic cells, as measured in ELISPOT assays. Also, DC and ATC are able to prime naíve T cells to develop into tumor-specific effector cells. Thus, ATC are shown to be a source of immunogenic antigens. This finding provides a good rationale for using ATC in DC-based vaccination trials.

    PubMed  CAS  Google Scholar 

  37. De Zoeten E, Carr-Brendel V, Markovic D, et al.: Immunity to breast cancer in mice immunized with semi-allogeneic fibroblasts transfected with DNA from breast cancer cells. J Immunol 1999, 162:6934–6941.

    PubMed  Google Scholar 

  38. Cohen EP: Cancer therapy with DNA-based vaccines. Immunol Lett 2000, 74:59–65. A comprehensive review of DNA-based vaccines, with a special focus on animal tumor models that amply demonstrate antitumor and survival benefits of this form of therapy.

    Article  PubMed  CAS  Google Scholar 

  39. Asai T, Storkus WJ, Whiteside TL: Evaluation of the modified ELISPOT assay for interferong production in cancer patients receiving anti-tumor vaccines. Clin Diagn Lab Immunol 2000, 7:145–154.

    Article  PubMed  CAS  Google Scholar 

  40. Nagashima S, Reichert TE, Kashii Y, et al.: In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2. Cancer Gene Ther 1997, 4:366–376.

    PubMed  CAS  Google Scholar 

  41. Sumareva R, Ukrainsky G, Kiremidjian-Schumacher L, et al.:Effect of combined adoptive immunotherapy and radiotherapy on tumor growth. Radiat Oncol Invest 1999, 7:22–29.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Pittsburgh Cancer Institute and Departments of Pathologyand Otolaryngology, University of Pittsburgh School of Medicine, W1041 Biomedical Science Tower, 211 Lothrop Street, 15213-2582, Pittsburgh, PA, USA

    Theresa L. Whiteside PhD

Authors
  1. Theresa L. Whiteside PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Whiteside, T.L. Immunobiology and immunotherapy of head and neck cancer. Curr Oncol Rep 3, 46–55 (2001). https://doi.org/10.1007/s11912-001-0042-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-001-0042-3

Keywords

Search

Navigation